Digital Therapeutic for Schizophrenia
A new smartphone app, CT-155, has shown promise in reducing negative symptoms of schizophrenia.
Developed by Boehringer Ingelheim and Click Therapeutics, CT-155 integrates psychosocial interventions using an adaptive goal-setting technique.
- A phase 3 trial demonstrated the app's effectiveness in reducing negative symptoms.
- The app exhibited good tolerability and no significant adverse events when used with antipsychotic treatment.
No significant adverse events were observed.
An estimated 24 million people worldwide have schizophrenia, according to the World Health Organization, characterized by persistent delusions and hallucinations.
Author's summary: Digital therapy CT-155 reduces schizophrenia symptoms.
More News
- Coffee's delicious journey from tiny bean to tasty brew
- BIG: Developer Successfully Ports NothingOS 4.0 to the Phone 1
- It's official - Pennsylvania, New Jersey and Delaware among states that must switch to daylight saving time - these are the ones that must not
- Knox County grand jury indictments: Manslaughter, arson, aggravated assault
- Boeing’s Arms Sales Thrive on Gaza Genocide
- Chelsea enjoy thumping win at Forest - West London Sport
- Dan's Daily: Jagr Back; Team USA Makes Demands; Penguins Changes
- First Alert Forecast: Dry, warm Saturday ahead of rainy Sunday morning
- Texas faces heightened wildfire threat amid ongoing drought